{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T05:17:07Z","timestamp":1737868627001,"version":"3.33.0"},"reference-count":22,"publisher":"The Fukushima Society of Medical Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2025]]},"DOI":"10.5387\/fms.24-00013","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T22:11:32Z","timestamp":1733523092000},"page":"63-68","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of anti-signal recognition particle antibody-positive myositis with intravenous cyclophosphamide: A case report"],"prefix":"10.5387","volume":"71","author":[{"given":"Jumpei","family":"Temmoku","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanae","family":"Tsuchihashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sumichika","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M.  Idiopathic inflammatory myopathies:a review.  <i>Intern Med J<\/i>, <b>51<\/b>:845-852, 2021.","DOI":"10.1111\/imj.15358"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Malik A, Hayat G, Kalia JS, Guzman MA.  Idiopathic Inflammatory Myopathies:Clinical Approach and Management.  <i>Front Neurol<\/i>, <b>7<\/b>:64, 2016.","DOI":"10.3389\/fneur.2016.00064"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Corona-Sanchez EG, Mart\u00ednez-Garc\u00eda EA, Lujano-Ben\u00edtez AV<i>, et al.<\/i>  Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies:Does the endoplasmic reticulum stress response have a role? <i>Front Immunol<\/i>, <b>13<\/b>:940122, 2022.","DOI":"10.3389\/fimmu.2022.940122"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Teel A, Lu J, Park J, Singh N, Basharat P.  The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies:A Systematic Review.  <i>Semin Arthritis Rheum<\/i>, <b>57<\/b>:152088, 2022.","DOI":"10.1016\/j.semarthrit.2022.152088"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ma X, Bu BT.  Anti-SRP immune-mediated necrotizing myopathy:A critical review of current concepts.  <i>Front Immunol<\/i>, <b>13<\/b>:1019972, 2022.","DOI":"10.3389\/fimmu.2022.1019972"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L.  Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies:a case series.  <i>Arthritis Care Res (Hoboken)<\/i>, <b>62<\/b>:1328-1334, 2010.","DOI":"10.1002\/acr.20219"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pinal-Fernandez I, Mammen AL.  Spectrum of immune-mediated necrotizing myopathies and their treatments.  <i>Curr Opin Rheumatol<\/i>, <b>28<\/b>:619-624, 2016.","DOI":"10.1097\/BOR.0000000000000335"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Suzuki S, Nishikawa A, Kuwana M<i>, et al.<\/i>  Inflammatory myopathy with anti-signal recognition particle antibodies:case series of 100 patients.  <i>Orphanet J Rare Dis<\/i>, <b>10<\/b>:61, 2015.","DOI":"10.1186\/s13023-015-0277-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Allenbach Y, Mammen AL, Benveniste O, Stenzel W.  224th ENMC International Workshop::Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.  <i>Neuromuscul Disord<\/i>, <b>28<\/b>:87-99, 2018.","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ascherman DP, Oriss TB, Oddis CV, Wright TM.  Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis.  <i>J Immunol<\/i>, <b>169<\/b>:7127-7134, 2002.","DOI":"10.4049\/jimmunol.169.12.7127"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Malmstr\u00f6m V, Venalis P, Albrecht I.  T cells in myositis.  <i>Arthritis Res Ther<\/i>, <b>14<\/b>:230, 2012.","DOI":"10.1186\/ar4116"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Aggarwal R, Oddis CV, Goudeau D<i>, et al.<\/i>  Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.  <i>Rheumatology (Oxford)<\/i>, <b>55<\/b>:991-999, 2016.","DOI":"10.1093\/rheumatology\/kev444"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Carstens PO, M\u00fcllar LM, Wrede A<i>, et al.<\/i>  Skeletal muscle fibers produce B-cell stimulatory factors in chronic myositis.  <i>Front Immunol<\/i>, <b>14<\/b>:1177721, 2023.","DOI":"10.3389\/fimmu.2023.1177721"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA.  Rituximab in the treatment of inflammatory myopathies:a review.  <i>Rheumatology (Oxford)<\/i>, <b>56<\/b>:26-36, 2017.","DOI":"10.1093\/rheumatology\/kew146"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C.  Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies:A systematic review and meta-analysis.  <i>Front Immunol<\/i>, <b>13<\/b>:1051609, 2022.","DOI":"10.3389\/fimmu.2022.1051609"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pinal-Fernandez I, Parks C, Werner JL<i>, et al.<\/i>  Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.  <i>Arthritis Care Res (Hoboken)<\/i>, <b>69<\/b>:263-270, 2017.","DOI":"10.1002\/acr.22920"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Brummaier T, Pohanka E, Studnicka-Benke A, Pieringer H.  Using cyclophosphamide in inflammatory rheumatic diseases.  <i>Eur J Intern Med<\/i>, <b>24<\/b>:590-596, 2013.","DOI":"10.1016\/j.ejim.2013.02.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Maher TM, Tudor VA, Saunders P<i>, et al.<\/i>  Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL):a double-blind, double-dummy, randomised, controlled, phase 2b trial.  <i>Lancet Respir Med<\/i>, <b>11<\/b>:45-54, 2023.","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Moreno-Torres V, Mart\u00edn-Iglesias D, Vivero F<i>, et al.<\/i>  Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies.  <i>Semin Arthritis Rheum<\/i>, <b>59<\/b>:152164, 2023.","DOI":"10.1016\/j.semarthrit.2023.152164"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Quan XY, Chen HT, Liang SQ<i>, et al.<\/i>  Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.  <i>Biomed Res Int<\/i>, <b>2022<\/b>:8345737, 2022.","DOI":"10.1155\/2022\/8345737"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ysermans R, Busch MH, Aendekerk JP, Damoiseaux J, van Paassen P.  Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis:A retrospective study.  <i>J Transl Autoimmun<\/i>, <b>6<\/b>:100178, 2023.","DOI":"10.1016\/j.jtauto.2022.100178"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mecoli CA, Lahouti AH, Brodsky RA, Mammen AL, Christopher-Stine L.  High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.  <i>Neurol Neuroimmunol Neuroinflamm<\/i>, <b>4<\/b>:e381, 2017.","DOI":"10.1212\/NXI.0000000000000381"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/71\/1\/71_24-00013\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:50:02Z","timestamp":1737780602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/71\/1\/71_24-00013\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.24-00013","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"type":"print","value":"0016-2590"},{"type":"electronic","value":"2185-4610"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"24-00013"}}